Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
G. Zuglian, D. Ripamonti, A. Tebaldi and 1 more
Medical Mycology Case Reports · 2019
doi:10.1016/j.mmcr.2019.10.002 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option. Keywords: Mucormycosis, Cutaneous, Immunocompromised, Isavuconazole
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.